2-(7-hydroxy-5-oxo-3-(6-(trifluoromethyl)pyridin-3-yl)-3,5-dihydro-2H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxamido)acetic acid

ID: ALA4552680

Chembl Id: CHEMBL4552680

PubChem CID: 121246837

Max Phase: Preclinical

Molecular Formula: C20H14F3N3O6

Molecular Weight: 449.34

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C(O)CNC(=O)c1c(O)c2cccc3c2n(c1=O)C(c1ccc(C(F)(F)F)nc1)CO3

Standard InChI:  InChI=1S/C20H14F3N3O6/c21-20(22,23)13-5-4-9(6-24-13)11-8-32-12-3-1-2-10-16(12)26(11)19(31)15(17(10)29)18(30)25-7-14(27)28/h1-6,11,29H,7-8H2,(H,25,30)(H,27,28)

Standard InChI Key:  HCEPLKRFRYQEBZ-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4552680

    ---

Associated Targets(Human)

EGLN3 Tclin Egl nine homolog 3 (250 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGLN1 Tclin Egl nine homolog 1 (1702 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EGLN2 Tclin Hypoxia-inducible factor prolyl hydroxylase 1 (404 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 449.34Molecular Weight (Monoisotopic): 449.0835AlogP: 1.92#Rotatable Bonds: 4
Polar Surface Area: 130.75Molecular Species: ACIDHBA: 7HBD: 3
#RO5 Violations: HBA (Lipinski): 9HBD (Lipinski): 3#RO5 Violations (Lipinski):
CX Acidic pKa: 3.01CX Basic pKa: 1.09CX LogP: 0.60CX LogD: -5.07
Aromatic Rings: 3Heavy Atoms: 32QED Weighted: 0.55Np Likeness Score: -0.39

References

1. Liu P, Wang L, DuBois BG, Colandrea VJ, Liu R, Cai J, Du X, Quan W, Morris W, Bai J, Bishwokarma B, Cheng M, Piesvaux J, Ray K, Alpert C, Chiu CS, Zielstorff M, Metzger JM, Yang L, Leung D, Alleyne C, Vincent SH, Pucci V, Li X, Crespo A, Stickens D, Hale JJ, Ujjainwalla F, Sinz CJ..  (2018)  Discovery of Orally Bioavailable and Liver-Targeted Hypoxia-Inducible Factor Prolyl Hydroxylase (HIF-PHD) Inhibitors for the Treatment of Anemia.,  (12): [PMID:30613325] [10.1021/acsmedchemlett.8b00274]

Source